03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss.

The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier.

Analysts polled by Capital IQ expected a $0.18 loss.

Revenue for the quarter ended June 30 grew to $73.8 million from $25.8 million a year earlier.

Analysts expected $47.5 million.

As of June 30, Esperion Therapeutics ( ESPR ) said it had $189.3 million in cash and cash equivalents.

Price: 1.86, Change: -0.16, Percent Change: -7.92